scholarly journals Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon

2017 ◽  
Vol 10 (5) ◽  
pp. 719-725 ◽  
Author(s):  
Jiayi Yu ◽  
Xiaowen Wu ◽  
Huan Yu ◽  
Siming Li ◽  
LiLi Mao ◽  
...  
Keyword(s):  
T Cell ◽  
High Risk ◽  
High Dose ◽  
Acral Melanoma ◽  
Melanoma Patients ◽  
Immune Inflammation ◽  
High Dose Interferon

Association of immune-inflammation index with outcome of high-risk acral melanoma patients treated with adjuvant high-dose interferon.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e21070-e21070 ◽  
Author(s):  
Jiayi Yu ◽  
Si Ming Li ◽  
Yan Kong ◽  
Lu Si ◽  
Xinan Sheng ◽  
...  
Keyword(s):  
High Risk ◽  
High Dose ◽  
Acral Melanoma ◽  
Melanoma Patients ◽  
Immune Inflammation ◽  
High Dose Interferon

A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients

2011 ◽  
Vol 47 (10) ◽  
pp. 1498-1503 ◽  
Author(s):  
Lili Mao ◽  
Lu Si ◽  
Zhihong Chi ◽  
Chuanliang Cui ◽  
Xinan Sheng ◽  
...  
Keyword(s):  
High Risk ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Interferon Α ◽  
High Dose ◽  
Acral Melanoma ◽  
Melanoma Patients ◽  
High Dose Interferon

Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21516-e21516
Author(s):  
Jiuhong Wang ◽  
Jingjing Li ◽  
Xing Liu ◽  
Xizhi Wen ◽  
Dandan Li ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Chinese Patients ◽  
Interferon Α ◽  
High Dose ◽  
Free Survival ◽  
Acral Melanoma ◽  
Treatment Groups ◽  
Melanoma Patients ◽  
Metastatic Sites ◽  
High Dose Interferon

e21516 Background: The clinical efficacy of PD-1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. Methods: Thus, this single-centre, retrospective study analysed the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or acral melanoma who received either adjuvant PD-1 inhibitor or high-dose interferon α-2b (HDI). Propensity score matching (PSM) was used to control baseline differences between the two treatment groups. The primary end point was recurrence-free survival (RFS), and the secondary end points included distance metastasis-free survival (DMFS) and incidence of first distant metastatic sites. Results: Anti-PD-1 treatment resulted in significantly longer RFS (18-month RFS, 53.3% versus 26.7%; 95% CI, 0.097-0.975; P < 0.05) and DMFS (18-month DMFS, 70.9% versus 46.1%; 95% CI, 0.13-0.945; P < 0.05) than HDI in cutaneous melanoma patients. However, adjuvant anti-PD-1 treatment had no advantage over HDI in acral melanoma patients (18-month RFS, 30.0% versus 35.9%; P > 0.05; 18-month DMFS, 36.5% versus 63.6%; P > 0.05). The incidence of lung metastasis at first in the anti-PD-1 group was found to be significantly lower (12.5% versus 48.5%; P < 0.05) in cutaneous melanoma patients than in acral melanoma patients, but no difference in metastatic sites were observed between the two treatment groups among acral melanoma patients. The incidence of treatment-related AEs was similar between the two treatment groups. Conclusions: In conclusion, adjuvant anti-PD-1 treatment was well tolerated and yielded a significantly better prognosis than HDI in Chinese patients with stage IIIB/C cutaneous melanoma, but a significant difference was not observed in those with acral melanoma.

Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B

2002 ◽  
Vol 25 (6) ◽  
pp. 591-596 ◽  
Author(s):  
Helen Gogas ◽  
George Paterakis ◽  
Konstantina Frangia ◽  
Dimitrios Bafaloukos ◽  
Dimitrios Pectasides ◽  
...  
Keyword(s):  
High Risk ◽  
Lymphocyte Subpopulations ◽  
High Dose ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
High Dose Interferon

Dose-Dependent Treatment Benefit in High-Risk Melanoma Patients Receiving Adjuvant High-Dose Interferon Alfa-2b

2005 ◽  
Vol 20 (3) ◽  
pp. 280-289 ◽  
Author(s):  
Michael Fluck ◽  
Darab Kamanabrou ◽  
Andrea Lippold ◽  
Martina Reitz ◽  
Jens Atzpodien
Keyword(s):  
High Risk ◽  
Interferon Alfa ◽  
High Dose ◽  
Treatment Benefit ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Dose Dependent ◽  
High Dose Interferon

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

2001 ◽  
Vol 19 (9) ◽  
pp. 2370-2380 ◽  
Author(s):  
John M. Kirkwood ◽  
Joseph G. Ibrahim ◽  
Jeffrey A. Sosman ◽  
Vernon K. Sondak ◽  
Sanjiv S. Agarwala ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Risk ◽  
Interferon Alfa ◽  
High Dose ◽  
Treatment Benefit ◽  
Significant Treatment ◽  
Melanoma Patients ◽  
Intergroup Trial ◽  
Resected Stage ◽  
High Dose Interferon

PURPOSE: Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard adjuvant therapy for high-risk melanoma, are of interest because of toxicity associated with HDI. The GM2 ganglioside is a well-defined melanoma antigen, and anti-GM2 antibodies have been associated with improved prognosis. We conducted a prospective, randomized, intergroup trial to evaluate the efficacy of HDI for 1 year versus vaccination with GM2 conjugated to keyhole limpet hemocyanin and administered with QS-21 (GMK) for 96 weeks (weekly × 4 then every 12 weeks × 8). PATIENTS AND METHODS: Eligible patients had resected stage IIB/III melanoma. Patients were stratified by sex and number of positive nodes. Primary end points were relapse-free survival (RFS) and overall survival (OS). RESULTS: Eight hundred eighty patients were randomized (440 per treatment group); 774 patients were eligible for efficacy analysis. The trial was closed after interim analysis indicated inferiority of GMK compared with HDI. For eligible patients, HDI provided a statistically significant RFS benefit (hazard ratio [HR] = 1.47, P = .0015) and OS benefit (HR = 1.52, P = .009) for GMK versus HDI. Similar benefit was observed in the intent-to-treat analysis (RFS HR = 1.49; OS HR = 1.38). HDI was associated with a treatment benefit in all subsets of patients with zero to ≥ four positive nodes, but the greatest benefit was observed in the node-negative subset (RFS HR = 2.07; OS HR = 2.71 [eligible population]). Antibody responses to GM2 (ie, titers ≥ 1:80) at days 29, 85, 365, and 720 were associated with a trend toward improved RFS and OS (P2 = .068 at day 29). CONCLUSION: This trial demonstrated a significant treatment benefit of HDI versus GMK in terms of RFS and OS in melanoma patients at high risk of recurrence.

Sign in / Sign up

Export Citation Format

Share Document